Citations

Mayo Clinic

Showing 10 of 108551 citations.

The spectrum of low-output low-gradient aortic stenosis with normal ejection fraction
Pislaru, Sorin V. , Pellikka, Patricia A. , Sabbah, Michael S. , Pellikka, Patricia A

Heart | February 14, 2016 | Volume: 102 | Issue: 9 | Pages: 665-671

10.1136/heartjnl-2015-307893 | PMID 26822426 Get It

Low-flow, low-gradient (LF/LG) severe aortic stenosis (AS) with preserved ejection fraction refers to the condition of AS with aortic valve area ≤1 cm2, stroke volume index <35 mL/m2, mean aortic valve gradient <40 mm Hg and left ventricular ejection fraction ≥50%. This mismatch of aortic valve area suggesting severe stenosis and ‘low’ gradient in some patients has led to confusion as to the severity of stenosis. Conditions previously labelled as LF/LG severe AS include a spectrum, with measurement error probably being the most common cause of marked inconsistency between gradient, valve area and patient presentation. The presence of LG severe AS may be overestimated in petite patients, who may have aortic valve area slightly less than 1 cm2 with only moderate AS. Concomitant cardiac conditions besides AS, including significant mitral and tricuspid regurgitation, intracardiac shunts and constrictive pericarditis, may contribute to reduced stroke volume, and evidence for these must be sought at the time of echocardiography. True LF/LG severe AS is associated with a unique and probably maladaptive remodelling pattern with smaller ventricles, increasing relative wall thickness, progressive worsening of diastolic function and higher afterload, as demonstrated by lower systemic arterial compliance, higher systemic vascular resistance and higher valvuloarterial impedance. Control of hypertension is essential to the appropriate management of patients with AS. Aortic valve replacement should be considered in patients with compelling evidence of severe AS who remain symptomatic despite optimal treatment of hypertension.
Epigenetic Studies Point to DNA Replication/Repair Genes as a Basis for the Heritable Nature of Long Term Complications in Diabetes
Leontovich, Alexey A. , Intine, Robert V., Sarras, Michael P.

Journal of Diabetes Research | February 14, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-10

10.1155/2016/2860780 | PMID 26981540 Get It

Metabolic memory (MM) is defined as the persistence of diabetic (DM) complications even after glycemic control is pharmacologically achieved. Using a zebrafish diabetic model that induces a MM state, we previously reported that, in this model, tissue dysfunction was of a heritable nature based on cell proliferation studies in limb tissue and this correlated with epigenetic DNA methylation changes that paralleled alterations in gene expression. In the current study, control, DM, and MM excised fin tissues were further analyzed by MeDIP sequencing and microarray techniques. Bioinformatics analysis of the data found that genes of theDNA replication/DNA metabolism processgroup (with upregulation of theapex1, mcm2, mcm4, orc3,lig1, anddnmt1 genes) were altered in the DM state and these molecular changes continued into MM. Interestingly, DNA methylation changes could be found as far as 6–13 kb upstream of the transcription start site for these genes suggesting potential higher levels of epigenetic control. In conclusion, DNA methylation changes in members of theDNA replication/repair processgroup best explain the heritable nature of cell proliferation impairment found in the zebrafish DM/MM model. These results are consistent with human diabetic epigenetic studies and provide one explanation for the persistence of long term tissue complications as seen in diabetes.
Splenomegaly and thrombosis risk in essential thrombocythemia: the mayo clinic experience
Haider, Mahnur , Gangat, Naseema , Hanson, Curtis A. , Tefferi, Ayalew , Hanson, Curtis

American Journal of Hematology | February 14, 2016 | Volume: 91 | Issue: 5 | Pages: No page available

10.1002/ajh.24334 | PMID 26875150 Get It

Spur cell anemia in the setting of progressive liver allograft failure
Partain, Daniel K. , Poterucha, John J., Ashrani, Aneel A. , Thompson, Carrie A. , Botero, Juliana Perez , Shi, Min , Partain, Daniel K

American Journal of Hematology | February 14, 2016 | Volume: 91 | Issue: 10 | Pages: 1061-1061

10.1002/ajh.24331 | PMID 26874796 Get It

Nodular Fasciitis of the Orbit: A Case Report Confirmed by Molecular Cytogenetic Analysis
Anzeljc, Andrew J., Oliveira, André M. , Kim, Hee Joon , Hayek, Brent , Grossniklaus, Hans E.

Ophthalmic Plastic & Reconstructive Surgery | February 14, 2016 | Volume: 33 | Issue: 3S | Pages: S152-S155

10.1097/iop.0000000000000649 | PMID 26882059 Get It

Nodular fasciitis is a benign fibroblastic proliferation typically found in the subcutaneous tissue or superficial fascia of the extremities that is often confused for malignancy. These lesions rarely occur on the eyelids and ocular adnexa and are seldom analyzed by ophthalmic pathologists. USP6 gene rearrangement has been recently demonstrated in nodular fasciitis and this rearrangement may lead to the formation of a fusion gene MYH9-USP6 in some cases. Herein, the authors describe a 38-year-old woman with a 6-month history of a progressively enlarging mass beneath her right medial upper eyelid. Histopathologic analysis of the excisional biopsy confirmed classic features of nodular fasciitis. Molecular cytogenetic analysis revealed a rearrangement of the USP6 locus, confirming the diagnosis of benign nodular fasciitis.
Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS‐T) and the role of next‐generation sequencing
Patnaik, Mrinal M. , Finke, Christy M. , Hanson, Curtis A. , King, Rebecca L. , Ketterling, Rhett P. , Gangat, Naseema , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P

American Journal of Hematology | February 14, 2016 | Volume: 91 | Issue: 5 | Pages: 492-498

10.1002/ajh.24332 | PMID 26874914 Get It

Refractory anemia with ring sideroblasts and thrombocytosis (RARS‐T) shares overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). RARS‐T is characterized by SF3B1 and JAK2 mutations and prognosis is considered to be better than MDS but not as good as MPN. The objective of the study was to identify predictors of survival in RARS‐T. We analyzed clinical and laboratory variables in 82 patients and applied a 27‐gene NGS assay to 48 marrow samples obtained at diagnosis. 94% of patients had ≥1 mutations; common mutations being: SF3B1 85%, JAK2 V617F 33%, ASXL1 29%, DNMT3A 13%, SETBP1 13% and TET2 10%. In a multivariable survival analysis ( n = 82), anemia ( P = 0.02) [HB< 10 gm/dl: HR 2.3, 95% CI 1.2–4.6] and abnormal karyotype ( P =.01) [HR 6.1, 95% CI 2.7‐13.8] were independently prognostic for inferior survival. In patients with NGS information ( n = 48), univariate analysis showed association between poor survival and presence of SETBP1 ( P = 0.04) or ASXL1 ( P = 0.08) mutations whereas the absence of these mutations ( ASXL1 wt/ SETBP1 wt) was favorable ( P = 0.04); the number of concurrent mutations did not provide additional prognostication ( P = 0.3). We developed a HR‐weighted prognostic model, with 2 points for an abnormal karyotype, 1 point for either ASXL1 and/or SETBP1 mutations, and 1 point for a HB level < 10 gm/dl, which effectively stratified patients into three risk categories; low (0 points), intermediate (1 point) and high (≥2 points), with median survivals of 80, 42 and 11 months respectively ( P = 0.01). In summary, we confirm the unique mutational landscape in RARS‐T and provide a novel mutation‐enhanced prognostic model. Am. J. Hematol. 91:492–498, 2016. © 2016 Wiley Periodicals, Inc.
Increased Operative Time for Benign Cranial Nerve Tumor Resection Correlates with Increased Morbidity Postoperatively
Murphy, Meghan E. , Gilder, Hannah E., McCutcheon, Brandon A., Kerezoudis, Panagiotis , Rinaldo, Lorenzo , Shepherd, Daniel , Maloney, Patrick R. , Snyder, Kendall, Carlson, Matthew L. , Link, Michael J., Bydon, Mohamad , Murphy, Meghan, Gilder, Hannah, Maloney, Patrick , Van Gompel, Jamie J, Carter, Bob S. , Gompel, Jamie J. Van

Journal of Neurological Surgery Part B: Skull Base | February 13, 2016 | Volume: 77 | Issue: 04 | Pages: 350-357

10.1055/s-0036-1572508 | PMID 27441161 Get It

Entrapment of a Pacing Lead within a Chiari Network: Utility of Intracardiac Echo and a Laser Sheath
Aung, Htin , Espinosa, Raúl E. , Powell, Brian D. , McLeod, Christopher J.

Pacing and Clinical Electrophysiology | February 13, 2016 | Volume: 39 | Issue: 6 | Pages: 620-622

10.1111/pace.12828 | PMID 26873294 Get It

Granulomatosis with polyangiitis mimicking classic inflammatory bowel disease-associated pyoderma gangrenosum
Kindle, Scott A., Camilleri, Michael , Gibson, Lawrence E. , Davis, Mark D.P.

International Journal of Dermatology | February 13, 2016 | Volume: 56 | Issue: 1 | Pages: e1-e3

10.1111/ijd.13218 | PMID 26873008 Get It

Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience
Kindle, Scott A., Wetter, David A. , Davis, Mark D.P. , Pittelkow, Mark R. , Sciallis, Gabriel F.

International Journal of Dermatology | February 13, 2016 | Volume: 55 | Issue: 8 | Pages: No page available

10.1111/ijd.13226 | PMID 26873674 Get It

AbstractBackgroundPublished case series describe lenalidomide as an effective treatment of refractory cutaneous lupus erythematosus (CLE).ObjectivesThe present study aimed to further characterize lenalidomide use in the treatment of CLE.MethodsA retrospective review of patients treated with lenalidomide for CLE from January 1, 2000, to December 17, 2014, was conducted.ResultsEight of the nine patients (89%) were women. Their median age at initiation of lenalidomide was 62 years (range: 41–86 years). Subtypes of CLE included discoid lupus erythematosus (DLE) (n = 6), lupus panniculitis (n = 2), and subacute CLE (n = 1). Before the initiation of lenalidomide, all patients had been previously treated unsuccessfully or were intolerant to at least one antimalarial and one immunosuppressive agent. With lenalidomide, five patients achieved a complete response (CR), two a partial response, and two had no response (lupus panniculitis). Time to initial response (dose range: 2.5–10.0 mg/d) varied from 2 weeks to 3 months; the median time to CR in five patients was 3 months (range: 3–6 months). The median duration of lenalidomide therapy was 12 months (range: 2–67 months). The median duration of follow‐up was 48 months (range: 20–103 months). Adverse effects included mild leukopenia; one patient had deep vein thrombosis of unclear etiology during a hospitalization. No patients developed or showed progression of systemic LE while receiving lenalidomide.ConclusionsLenalidomide was effective for the treatment of CLE (particularly DLE) but not for the treatment of lupus panniculitis in this series.